Oesophagogastric cancer has 1.7 million new cases per year globally. Five-year survival in the UK is 15–20%. Tumour hypoxia occurs when rapidly growing tumours outstrip their oxygen supply, triggering adaptive metabolic and genomic mutations that lead to highly aggressive, treatment-resistant cancers. There are currently no established methods for identifying hypoxic tumours in oesophagogastric cancer. By adapting the breath test model, patients with hypoxic tumours could be detected and offered targeted therapies.
Aims
Methods
Single-centre observational study at Imperial College London. Two arms: Pimonidazole arm (10 patients given a hypoxia-labelling agent prior to surgery) and Biosampling arm (100 patients). Utilises spatial transcriptomic, lipidomic, and pathway analysis to characterise hypoxia-driven VOC signatures.
Recruitment to this trial takes place through participating NHS centres. If you think you may be eligible, please speak with your GP or hospital clinician who can refer you through the appropriate pathway.
Healthcare professional enquiries: Nader Habib Bedwani